BioScrip Announces an $80 Million After-Tax Non-Cash Impairment Charge
This write off and impairment are the result of adverse equity and other
market conditions which caused a decrease in current market valuations
in the healthcare services industry and BioScrip’s stock price relative
to its book value at
BioScrip’s management performed its required testing of goodwill using a
discounted cash flow analysis supported by comparative market multiples
to determine the fair value of each of its businesses as compared to
their respective book values as of
About
Forward Looking Statements
This press release may contain statements which constitute forward
looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements regarding the
intent, belief or current expectations of the Company, its directors, or
its officers with respect to the future operating performance of the
Company and our success with respect to the integration and
consolidation. Investors are cautioned that any such forward looking
statements are not guarantees of future performance and involve risks
and uncertainties, and that actual results may differ materially from
those in the forward looking statements as a result of various factors.
Important factors that could cause such differences are described in the
Company's periodic filings with the
Source:
BioScrip, Inc.
Stanley G. Rosenbaum, 952-979-3768
EVP, Chief
Financial Officer
srosenbaum@bioscrip.com
or
In-Site
Communications
Lisa Wilson, 917-543-9932
lwilson@insitecony.com